Pregled bibliografske jedinice broj: 584972
Innovation in the biotechnology industry: The role of university-generated intellectual property rights, knowledge base investments and funding mechanisms
Innovation in the biotechnology industry: The role of university-generated intellectual property rights, knowledge base investments and funding mechanisms // Proceedings of the DRUID Society 2012 conference on "Innovation and Competitiveness: Dynamics of Organizations, Industries, Systems and Regions", Copenhagen, Denmark
Kopenhagen, Danska, 2012. str. 1-21 (predavanje, međunarodna recenzija, cjeloviti rad (in extenso), znanstveni)
CROSBI ID: 584972 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Innovation in the biotechnology industry: The role of university-generated intellectual property rights, knowledge base investments and funding mechanisms
Autori
Gerbin, Ani ; Drnovsek, Mateja
Vrsta, podvrsta i kategorija rada
Radovi u zbornicima skupova, cjeloviti rad (in extenso), znanstveni
Izvornik
Proceedings of the DRUID Society 2012 conference on "Innovation and Competitiveness: Dynamics of Organizations, Industries, Systems and Regions", Copenhagen, Denmark
/ - , 2012, 1-21
Skup
The DRUID Society 2012 conference on "Innovation and Competitiveness: Dynamics of Organizations, Industries, Systems and Regions"
Mjesto i datum
Kopenhagen, Danska, 19.06.2012. - 21.06.2012
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
biotechnology industry ; innovation ; knowledge base ; patents ; shareholder value ; innovative enterprise
Sažetak
The purpose of this paper is to analyze determinants of innovation process effectiveness in the health care biotechnology industry. We use empirical data to highlight specific differences between Europe and USA. We build from a body of literature investigating the historical development of the industry, expansion of intellectual property rights to new entities and new scientific fields as well as the role of different sources of funding of biomedical commercialization process in the development of companies' innovative capabilities and new value creation. The theory of innovative enterprise with its focus on strategic control, financial commitment, and organizational integration is compared with the maximizing shareholder value concept in assessing the determinants of biotechnology innovation effectiveness. Our findings point to the weaknesses of the highly monetized US business model given the tendencies of the European biotechnology industry to emulate this model. Based on our findings we propose recommendations that should facilitate sustainable growth of the sector.
Izvorni jezik
Engleski
Znanstvena područja
Ekonomija
